Eumentis Therapeutics, Inc. — Form D
Eumentis Therapeutics, Inc. of NEWTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2020-09-02. The offering totals $3.3M, of which $1.5M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-09-02
- Form: D
- Accession: 0001805048-20-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $3.3M
- Amount sold: $1.5M
- Remaining: $1.8M
- Minimum investment: $25K
- Investors: 25
- Date of first sale: 2018-08-14
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-374718
Issuer
- Name: Eumentis Therapeutics, Inc.
- CIK: 0001823359
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 508 DUDLEY ROAD, NEWTON, MA, 02459
- Phone: 6174133020
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Maryann Bryla | Director | Newton, MA |
| James Larrick | Director | Osage Beach, MO |
| Randall Marshall | Executive Officer | Newton, MA |
| Kim Patrick | Director | Newton, MA |
| Mark Tepper | Director | Newton, MA |
| Mark Tepper | Executive Officer | Newton, MA |
| Andrew Pearlman | Director | Newton, MA |
| Amar Kapur | Director | Newton, MA |
Other filings by this issuer (3)
More